expression in general by binding to the 3′UTR of target mRNAs. 9, 10 miRNAs act as oncogenes or tumor suppressors in tumors dependent on special conditions. 11, 12 miRNAs are also involved in regulating the progression of cancers and CSCs. 13, 14 For instance, miR-429 drives liver tumor-initiating cell properties by targeting Rb binding protein 4. 15 Recent studies reported that miR-365 suppresses the proliferation and invasion of numerous tumors including breast cancer, gastric cancer, and liver cancer, [16] [17] [18] suggesting that this miRNA was associated with tumor initiation and progression. For instance, miR-365 suppressed HCC cells growth and metastasis by targeting ADAM10. 19 miR-365 also induced HCC cells apoptosis through targeting Bcl-2. 20 Development of HCC can be driven by a small heterogeneous population of tumor-derived cancer stem cells (CSCs).
Liver CSCs were participated in tumor propagation, resistance to conventional therapy, and promotion of tumor recurrence, causing poor patient outcomes. However, the regulatory role of miR-365 in liver CSCs remains unknown.
In the present study, we for first find that miR-365 was downregulated in liver CSCs. Next, by using gain-of-function analysis in HCC cells, we demonstrate that miR-365 could inhibit the selfrenewal capacity of liver CSCs. Further mechanism study reveals that miR-365 directly regulated RAC1 by binding with its mRNA 3′UTR.
RAC1 special inhibitor EHop-106 could abolish the self-renewal discrepancy between miR-365 overexpression HCC cells and control cells. We also found that miR-365 could affect the drug resistance of HCC cells to sorafenib and cisplatin. Taken together, our study shows that miR-365 is a novel cancer stem cell marker that plays a key role in liver CSCs expansion and drug resistance of HCC.
| MATERIALS AND METHODS

| Patients and samples
Total 100 HCC patients' tissue samples were collected from the Gansu provincial hospital (Gansu, China). Patient informed consent was also obtained and the procedure of human sample collection was approved by the Ethic Committee of Gansu provincial hospital.
| Cell lines and cell culture
HCC cell lines HCCLM3 and SMMC7721 were purchased form Chinese Academy of Sciences, Shanghai, China. The HCC cells were cultured with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine, and 25 μg/mL of gentamicin and maintained at 37°C in 5% CO 2 incubator.
The culture cells were digested with 0.5% trypsin and moved to a new plate twice a week.
The lenti-vector expressing miR-365 or RAC1 and their control virus were produced as described previously. 21 The lentiviral vectors were purchased from Shanghai GenePharma (Shanghai, China HCCLM3 and SMMC7721 were treated with FH535 (40 nM), SIS3
(1 µM), S3I-201 (100 µM) for 24 h and then subjected to real-time PCR assay.
| Cell proliferation assays
For cell proliferation analysis, SMMC7721 or HCCLM3 miR-365 and their control cells were seeded in 96-well plates (3 × 103 cells per well).
The hepatoma cells were treated with different doses sorafenib or cisplatin. ATP activity was measured using a Cell Counting Kit-8 at indicated time points. The procedure was as follows: The cell suspension (100 µL/well) was inoculated in a 96-well plate, and the plate was pre-incubated in a humidified incubator at 37°C for 1 h. This was followed by the addition of 10 µL of the CCK-8 solution to each well of the plate, and incubation of the plate for 1 h in the incubator.
Finally, the absorbance was measured at 450 nm using a microplate reader (Synergy H1; BioTek Instruments, Inc., Winooski, VT).
| Spheroid formation assay
SMMC7721 or HCCLM3 miR-365 and their control cells were cultured in a 6-or 96-well ultra-low attachment culture plate for 7 days, and the total number of spheres was counted under the microscope (Olympus, Beijing, China). 
| Limiting dilution assay
| Flow-cytometric analysis
Hepatoma cells were incubated with the primary anti-CD133 (Cat. no. 
| Statistical analysis
GraphPad Prism (GraphPad Software, Inc. La Jolla) was used for all statistical analyses. Statistical analysis was carried out using t-test or Bonferroni Multiple Comparisons Test: *P < 0.05. A P-value of less than 0.05 was considered significant.
3 | RESULTS
| miR-365 expression was preferentially downregulated in liver CSCs
To explore the function of miR-365 in HCC progression, we checked miR-365 expression by using a great amount of human HCC tissues.
As shown in Figure 1A , miR-365 expression was dramatically reduced in HCC cases compared with the paired non-tumorous tissues.
Considering the close association of liver CSCs with HCC recurrence and chemoresistance, we investigated the expression of miR-365 in liver CSCs. The expression of miR-365 was markedly downregulated in the self-renewing spheroids compared with the Figure 1C ). Cluster of differentiation 133 (CD133) and EpCAM are well-accepted liver CSCs marker. 23, 24 As expected, CD133+ and EpCAM+ liver CSCs sorted from trypsinized spheres of hepatoma cells displayed reduced miR-365 expression ( Figures 1D and 1E ). In comparison with control tumors, miR-365 expression was markedly decreased in the cisplatin-resistant HCC residual, indicating that miR-365 expression was associated with chemoresistance ( Figure 1F 
| miR-365 suppressed liver CSCs expansion
To further explore the role of miR-365 in liver CSCs, miR-365 stable overexpressing infectants of HCC cells were used (Figure 2A ). Flowcytometric analysis revealed a decreased proportion of liver CSCs in miR-365 stably transfected hepatoma cells (Figures 2B and 2C) . It was reported that the stem cell associated genes, including OCT4, SOX-2 and Nanog and so on, have important roles in liver CSCs regulation. [25] [26] [27] As expected, miR-365 overexpression downregulated the expression of stemness-associated genes ( Figures 3A and 3B ) and liver CSC markers in hepatoma cells ( Figures 3C and 3D ), which further supported that miR-365 could inhibit liver CSCs expansion.
| miR-365 affected the drug resistance of HCC cells to sorafenib and cisplatin
Liver CSCs were also involved in HCC chemoresistance and recurrence. 28 So we next explored the role of miR-365 in chemoresistance of HCC to sorafenib and cisplatin. As expected, we found that miR-365 expression was downregulated in cisplatin-resistant or sorafenib-resistant hepatoma cells ( Figures 4A and 4B ), suggesting miR-365 was involved in drug resistance. Furthermore, miR-365 overexpression dramatically increased the sensitivity of HCC cells to the same dosages of sorafenib or cisplatin ( Figures 4C and 4D ). In addition, the population of apoptotic cells was also significantly increased in hepatoma cells with miR-365 overexpression when exposed to sorafenib or cisplatin ( Figure 4E ). Taken together, these results demonstrated that drug sensitivity of HCC cells to sorafenib and cisplatin was significantly increased when miR-365 was overexpressing, suggesting a possible role of miR-365 in the treatment of HCC cells drug resistance.
| RAC1 was a direct target of miR-365 in HCC cells
Next, we attempted to identify the target genes of miR-365 that may be involved in liver CSCs expansion. Bioinformatics analysis suggested that RAC1 mRNA harbored a putative miR-365 binding site in its 3′-UTR ( Figure 5A ). To further explore whether miR-365 directly regulates RAC1 expression via interaction with its 3′-UTR, the wild- Figure 5D ). There was a significant negative correlation between miR-365 and RAC1 protein expression in HCC samples (r = 0.707, P < 0.001; Figure 5E ). These results suggested that RAC1
was a direct target of miR-365. To further confirm the role of RAC1 in miR-365-mediated expansion of liver CSCs, the special RAC1 inhibitor EHop-106 was used. 29 As expected, EHop-106 diminished the difference in liver CSC proportion between miR-365 overexpression hepatoma cells and control cells ( Figure 5M ). Consistently, EHop-106 entirely depleted the discrepancy of self-renewal capacity between miR-365 overexpression hepatoma cells and control cells ( Figure 5N ).
Collectively, these data suggest distinct regulation of RAC1 by miR-365 in liver CSCs. In present study, our data demonstrated that β-catenin inhibitor FH535 and SMAD3 inhibitor SIS3 was not influencing miR-365 expression in liver CSCs. However, the STAT3 inhibitor S3I-201 could dramatically upregulate miR-365 expression in liver CSCs ( Figure 6A ).
We also found high activity of STAT3 in liver CSCs than in normal HCC cell lines ( Figure 6B ). Moreover, STAT3 siRNA increased miR-365 expression in liver CSCs ( Figures 5C and 5D) . Consistently, overexpressing STAT3 also decreased miR-365 expression in liver CSCs ( Figures 5E and 5F ). These results remained us that miR-365 expression was regulated by JAK/STAT3 signaling pathway in liver
CSCs. The new data have been added into the revised manuscript.
| DISCUSSION
Hepatocellular carcinoma (HCC) is a worldwide and lethal cancer with high incidence and recurrence. 30 Only a part of HCC patients benefit from TACE or sorafenib treatment. 31 Most cancer therapies fail to eradicate tumors due to the existence of CSCs. 32 However, the understanding of regulatory mechanisms for CSCs is limited. In this study, we reported that miR-365 plays a pivotal role in liver CSC expansion and may serve as a therapeutic target in personalized treatment of HCC.
Accumulating evidence shows that miRNAs were involved in the initiation and progression of human cancers, 33 and may prove to be a novel marker for the diagnosis and treatment of cancers. It was reported that miR-365 worked as a tumor suppressor gene in numerous cancers. 34 miR-365 was also played an important role in liver cancer proliferation, metastasis and apoptosis. 35 However, the potential role of miR-365 in liver CSCs has not been reported. In our above work, we found that miR-365 overexpression by lenti-virus inhibited liver CSCs self-renew and dedifferentiation.
The existence of CSCs has been confirmed by numerous studies, and these cells have the ability to self-renew and the potential for generating heterogeneous malignant progenies. 36 It was accepted that liver CSCs were contributed to the chemoresistance and HCC recurrence. In the current study, liver CSCs were enriched by establishing chemoresistant HCC xenograft tumors, and expression of miR-365 in these chemoresistant xenografts was notably downregulated. Considering the importance of CSCs in tumor recurrence and chemoresistance, we investigated the influence of miR-365 on liver CSCs. Spheroid culture of cancer cells is a routine approach to enrich CSCs. We found that miR-365 expression was downregulated in hepatoma spheroids. Our data showed that miR-365 levels decreased in CD133+ or EpCAM+ liver CSCs. Moreover, miR-365 overexpression in hepatoma cells inhibited the self-renewal capacity of liver CSCs, and downregulated stemness-associated genes and liver CSC markers. We also observed that miR-365 overexpression HCC cells are more sensitivity to sorafenib and cisplatin treatment.
Ras-related C3 botulinum toxin substrate 1 (RAC1) is a pleiotropic regulator of many cellular processes, including the cell cycle, cell-cell adhesion, motility, and of epithelial differentiation. 37 Recent studies showed that RAC1 worked as an oncogene in many tumors, including breast cancer, melanoma, and liver cancer. [38] [39] [40] In the present study, we for the first time found that RAC1 was a direct target of miR-365.
Overexpression RAC1 also could promote the expansion of liver CSCs.
Overexpressing miR-365 in hepatoma cells downregulated RAC1 expression through binding to its 3′UTR. EHop-016, a novel Rac inhibitor, was derived on the basis of the structure of NSC23766 and inhibited the activation of Rac with a substantially lower IC50 compared with NSC23766. 41 In additional, EHop-016 could abolish the discrepancy of the self-renewal ability between miR-365 overexpression hepatoma cells and their control cells, which further confirm RAC1 was the downstream of miR-365 in regulating liver CSCs expansion.
Herein, we showed that miR-365 was downregulated in liver
CSCs, which in turn inhibited the expansion of liver CSCs. Moreover, miR-365 inhibited liver CSCs expansion via directly regulating RAC1 in vitro and in vivo. These findings of the present study not only shed a new light on the mechanism of liver CSCs but suggest a novel prognostic marker and a potential therapeutic target against HCC.
